|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Accuracy of Risk Scores for Patients With Chronic Hepatitis B Receiving Entecavir Treatment显示文摘 | Grace Lai–Hung Wong Henry Lik–Yuen Chan Hoi–Yun Chan Pete Chi–Hang Tse Yee–Kit Tse Christy Wing–Hin Mak Stanley King–Yeung Lee Zoe Man–Yi Ip Andrew Ting–Ho Lam Henry Wing–Hang Iu Joyce May–Sum Leung Vincent Wai–Sun Wong | 2013 | Gastroenterology2013，，5： | 2 |
| 2 | Structural prepayment risk behavior of the underlying mortgages for residential mortgage life insurance in a developing market显示文摘 | Kim Hin Ho Huiyong Su | | 0，，03： | 1 |
| 3 | Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis显示文摘 | Grace Lai‐Hung Wong Henry Lik‐Yuen Chan Christy Wing‐Hin Mak Stanley King‐Yeung Lee Zoe Man‐Yi Ip Andrew Ting‐Ho Lam Henry Wing‐Hang Iu Joyce May‐Sum Leung Jennifer Wing‐Yan Lai Angeline Oi‐Shan Lo Hoi‐Yun Chan Vincent Wai‐Sun Wong | 2013 | Hepatology2013，，5： | 1 |
| 4 | Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era显示文摘Hepatitis due to hepatitis B virus(HBV)reactivation can be serious and potentially fatal,but is preventable.HBV reactivation is most commonly reported in patients receiving chemotherapy,especially rituximab-containing therapy for hematological malignancies and those receiving stem cell transplantation.Patients with inactive and even resolved HBV infection still have persistence of HBV genomes in the liver.The expression of these silent genomes is controlled by the immune system.Suppression or ablation of immune cells,most importantly B cells,may lead to reactivation of seemingly resolved HBV infection.Thus,all patients with hematological malignancies receiving anticancer therapy should be screened for active or resolved HBV infection by blood tests for hepatitis B surface antigen(HBsAg)and antibody to hepatitis B core antigen.Patients found to be positive for HBsAg should be given prophylactic antiviral therapy.For patients with resolved HBV infection,there are two approaches.The first is pre-emptive therapy guided by serial HBV DNA monitoring,and treatment with antiviral therapy as soon as HBV DNA becomes detectable.The second approach is prophy-lactic antiviral therapy,particularly for patients receiving high-risk therapy,especially anti-CD20 monoclonal antibody or hematopoietic stem cell transplantation.Entecavir and tenofovir are the preferred antiviral choices.Many new effective therapies for hematological malignancies have been introduced in the past decade,for example,chimeric antigen receptor(CAR)-T cell therapy,novel monoclonal antibodies,bispecific antibody drug conjugates,and small molecule inhibitors,which may be associated with HBV reactivation.Although there is limited evidence to guide the optimal preventive measures,we recommend antivi-ral prophylaxis in HBsAg-positive patients receiving novel treatments,including Bruton’s tyrosine kinase inhibitors,B-cell lymphoma 2 inhibitors,and CAR-T cell therapy.Further studies are needed to determine the risk of HBV reactivation with these agents and the best prophylactic strategy. | Joyce Wing Yan Mak Alvin Wing Hin Law Kimmy Wan Tung Law Rita Ho Carmen Ka Man Cheung Man Fai Law | 2023 | World Journal of Gastroenterology2023，29，33： | 1 |
| 5 | Helicobacter pylori induces promoter methylation of E‐cadherin via interleukin‐1β activation of nitric oxide production in gastric cancer cells显示文摘 | Fung‐Yu Huang Annie On‐On Chan Asif Rashid Danny Ka‐Ho Wong Chi‐Hin Cho Man‐Fung Yuen | 2012 | Cancer2012，，20： | 1 |
| 6 | Correlation and Volatility Dynamics in International Real Estate Securities Markets显示文摘 | Kim Hiang Liow Kim Hin David Ho Muhammad Faishal Ibrahim Ziwei Chen | 2009 | The Journal of Real Estate Finance and Economics2009，，2： | 1 |
| 7 | Triglyceride concentration and ischemic heart disease:an eight-year follow-up in the Copenhagen male study显示文摘 | Jeppesen J Hin HO Suadicani P | 1998 | Circulation1998，97，11： | 1 |
| 8 | Structural prepayment risk behavior of the underlying mortgages for residential mortgage life insurance in a developing market显示文摘 | Kim Hin (David) Ho Huiyong Su | 2006 | Journal of Housing Economics2006，，3： | 1 |
| 9 | Modeling the structure of CV formation and expectations: The commercial retail real estate sector显示文摘 | Kim Hin (David) Ho | 2007 | Journal of Property Investment & Finance2007，，2： | 1 |
| 10 | Structural dynamics in the policy planning of large infrastructure investment under the competitive environment: context of port throughput and capacity 显示文摘 | KIM HIN DAVID HO MUN WAI HO CHI MAN EDDIE HUI | 2008 | Journal of Urban Planning and Development (ASCE)2008，3，： | 1 |
| 11 | Asset allocation:International real estate investment strategy under a workable analytic hierarchy process (AHP)显示文摘 | Kim Hin David Ho Seow Eng Ong Tien Foo Sing | 2006 | Journal of Property Investment & Finance2006，24，45： | 1 |
| 12 | Helicobacter pylori induces promoter methylation of E‐cadherin via interleukin‐1β activation of nitric oxide production in gastric cancer cells显示文摘 | Fung‐Yu Huang Annie On‐On Chan Asif Rashid Danny Ka‐Ho Wong Chi‐Hin Cho Man‐Fung Yuen | 2012 | Cancer2012，，20： | 1 |
| 13 | Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases显示文摘The outbreak of coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Vaccination against coronavirus disease 2019 is a use-ful weapon to combat the virus. Patients with chronic liver diseases (CLDs), including compensated or decompensated liver cirrhosis and noncirrhotic diseases, have a decreased immunologic response to coronavirus disease 2019 vaccines. At the same time, they have increased mortality if infected. Current data show a reduction in mortality when patients with chronic liver diseases are vaccinated. A suboptimal vac-cine response has been observed in liver transplant recipi-ents, especially those receiving immunosuppressive therapy, so an early booster dose is recommended to achieve a better protective effect. Currently, there are no clinical data com-paring the protective efficacy of different vaccines in patients with chronic liver diseases. Patient preference, availability of the vaccine in the country or area, and adverse effect profiles are factors to consider when choosing a vaccine. There have been reports of immune-mediated hepatitis after coronavi-rus disease 2019 vaccination, and clinicians should be aware of that potential side effect. Most patients who developed hepatitis after vaccination responded well to treatment with prednisolone, but an alternative type of vaccine should be considered for subsequent booster doses. Further prospec-tive studies are required to investigate the duration of immu-nity and protection against different viral variants in patients with chronic liver diseases or liver transplant recipients, as well as the effect of heterologous vaccination. | Carmen Ka Man Cheung Kimmy Wan Tung Law Alvin Wing Hin Law Man Fai Law Rita Ho Sunny Hei Wong | 2023 | Journal of Clinical and Translational Hepatology2023，11，3： | 0 |
| 14 | Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease显示文摘BACKGROUND Chronic liver disease(CLD)was associated with adverse clinical outcomes among people with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection.AIM To determine the effects of SARS-CoV-2 infection on the incidence and treatment strategy of hepatocellular carcinoma(HCC)among patients with CLD.METHODS A retrospective,territory-wide cohort of CLD patients was identified from an electronic health database in Hong Kong.Patients with confirmed SARS-CoV-2 infection[coronavirus disease 2019(COVID-19)+CLD]between January 1,2020 and October 25,2022 were identified and matched 1:1 by propensity-score with those without(COVID-19-CLD).Each patient was followed up until death,outcome event,or November 15,2022.Primary outcome was incidence of HCC.Secondary outcomes included all-cause mortality,adverse hepatic outcomes,and different treatment strategies to HCC(curative,non-curative treatment,and palliative care).Analyses were further stratified by acute(within 20 d)and post-acute(21 d or beyond)phases of SARS-CoV-2 infection.Incidence rate ratios(IRRs)were estimated by Poisson regression models.RESULTS Of 193589 CLD patients(>95%non-cirrhotic)in the cohort,55163 patients with COVID-19+CLD and 55163 patients with COVID-19-CLD were included after 1:1 propensity-score matching.Upon 249-d median follow-up,COVID-19+CLD was not associated with increased risk of incident HCC(IRR:1.19,95%CI:0.99-1.42,P=0.06),but higher risks of receiving palliative care for HCC(IRR:1.60,95%CI:1.46-1.75,P<0.001),compared to COVID-19-CLD.In both acute and post-acute phases of infection,COVID-19+CLD were associated with increased risks of allcause mortality(acute:IRR:7.06,95%CI:5.78-8.63,P<0.001;post-acute:IRR:1.24,95%CI:1.14-1.36,P<0.001)and adverse hepatic outcomes(acute:IRR:1.98,95%CI:1.79-2.18,P<0.001;post-acute:IRR:1.24,95%CI:1.13-1.35,P<0.001),compared to COVID-19-CLD.CONCLUSION Although CLD patients with SARS-CoV-2 infection were not associated with increased risk of HCC,they were more likely to receive palliative treatment than those without.The detrimental effects of SARS-CoV-2 infection persisted in post-acute phase. | Lung-Yi Mak Matthew Shing Hin Chung Xue Li Francisco Tsz Tsun Lai Eric Yuk Fai Wan Celine Sze Ling Chui Franco Wing Tak Cheng Esther Wai Yin Chan Ching Lung Cheung Ivan Chi Ho Au Xi Xiong Wai-Kay Seto Man-Fung Yuen Carlos King Ho Wong Ian Chi Kei Wong | 2024 | World Journal of Hepatology2024，16，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员